Advancing a class on top of statins
World Class Leadership

Medical and Scientific Advisory Board

Dyslipidemia
John Kastelein
John Kastelein

MD, PhD, FESC

Dr. Kastelein is a Medical Advisory Board member for Gemphire. Dr. Kastelein is Professor of Medicine, Chairman of the Department of Vascular Medicine, and Strategic Chair of Genetics in Cardiovascular Disease at the Academic Medical Center of the University of Amsterdam. In 2014, he was the Robert Levy Memorial Lecturer at American Heart Association Scientific Sessions. Dr. Kastelein has published over 740 research papers and he was one of the 3000 Highly Cited Researchers in 2014.

Evan Stein
Evan A. Stein

MD, PhD, FRCPC, FCAP

Dr. Stein is a Medical Advisory Board member for Gemphire. Dr. Stein is the director of the Cholesterol Treatment Center, and Director of the Metabolic and Atherosclerosis Research Center in Cincinnati. He is also the Voluntary Professor at the Pathology and Laboratory Medicine at the University of Cincinnati Medical Center. Dr. Stein is the Managing Partner of EVLIN Consultants. He founded PPD Global Central Labs in 1988, and he was an executive officer of Medpace Reference Laboratories.

Robert Hegele
Robert Hegele

MD, FRCPC, FACP, FAHA, FCAHS

Dr. Hegele is a Medical Advisory Board member for Gemphire. Dr. Hegele is a distinguished professor and research scientist of Robarts Research Institute and director of the Blackburn Cardiovascular Genetics Lab and London Regional Genomics Centre. He has over 600 publications and he was awarded for The Journal of Lipid Research Lectureship Award, 2012 Kern Lipid Conference.

Dirk Blom
Dirk Blom

PhD

Dr. Blom is a Medical Advisory Board member for Gemphire. Dr. Blom is the head of the Division of Lipidology at the University of Cape Town, head of the Lipid Clinic at Groote Schuur Hospital, and the member of executive committee of the Lipid and Atherosclerosis Society of Southern Africa. Dr. Blom is a member of South African Medical Association and South African Heart Association.

Harold Bays
Harold Bays

MD, FTOS, FACC, FACE, FNLA

Dr. Bays is a Medical and Scientific Advisory Board member for Gemphire. He has served as an Investigator in over 400 Phase I - IV clinical trials for treatments for high cholesterol and other dyslipidemias, obesity, diabetes mellitus, hypertension, osteoporosis, and other metabolic and hormonal disorders. Dr. Bays has served as Medical Director of L-MARC Research Center since 1989, and has served as President of L-MARC Research Center since its independent incorporation in 1998.

NASH
Scott Friedman
Scott Friedman

MD

Dr. Scott L. Friedman is the Dean for Therapeutic Discovery and Chief of the Division of Liver Diseases at the Icahn School of Medicine at Mount Sinai. He has performed pioneering research into the underlying causes of liver scarring, or fibrosis associated with chronic liver disease, affecting millions worldwide. Dr. Friedman was among the first to isolate and characterize the hepatic stellate cell, the key cell type responsible for scar production in liver. His work has spawned an entire field that is now realizing its translational and therapeutic potential, with new anti-fibrotic and NASH therapies for liver disease reaching clinical trials. Dr. Friedman’s work has been continuously funded by the NIH since 1985, and has authored over 300 peer-reviewed publications.

Dr. Friedman was a recipient in 1993 of the Saul Horowitz, Jr. Outstanding Alumnus Award from Mount Sinai. In 2003, Dr. Friedman was honored with the International Hans Popper Award by the Falk Foundation in Freiburg, Germany, in recognition of his outstanding contributions to the understanding of liver disease and its treatment. In 2012, he was awarded the European Association for the Study of Liver Diseases International Recognition Award in Barcelona, Spain, and in 2013 he was awarded the Shanghai Magnolia Gold Award by the Mayor of Shanghai and the China Friendship Award from the Premier of China in 2014, in recognition of his efforts to improve the health of the residents of Shanghai and China through his research achievements. In 2016, he was awarded the Distinguished Achievement Awards from both the AASLD and the American Liver Foundation.

As President of the American Assn. for the Study of Liver Diseases in 2009, Dr. Friedman oversaw several major new initiatives that accelerated its growth and brought the Association to new levels of income and international visibility.

Dr. Friedman’s appointment in 2012 as Dean for Therapeutic Discovery at Mount Sinai recognizes his unique strengths in translating basic science into clinically meaningful advances, and his investigative work in liver disease has been instrumental in fueling the tremendous growth in emerging diagnostics and therapeutics for hepatic fibrosis.

Rohit Loomba
Rohit Loomba

MD, MHSc

Dr. Loomba is a Medical and Scientific Advisory Board member for Gemphire. He is an expert in the clinical management of chronic liver diseases and holds a joint appointment in the Division of Gastroenterology in the Department of Medicine and the Division of Epidemiology in the Department of Family and Preventive Medicine, University of California at San Diego School of Medicine. Dr. Loomba’s research focuses on all aspects of nonalcoholic fatty liver disease including aging, epidemiology, genetic and environmental predisposition, natural history, and treatment of nonalcoholic steatohepatitis (NASH).

Mechanism of Action
Gerald Watts
Gerald Watts

DSc MD PhD FRCP FRACP

Dr. Watts is a Medical and Scientific Advisory Board member for Gemphire. Gerald Watts trained at Imperial and King’s Colleges, London University, United Kingdom. He is a senior consultant physician, specializing in cardiometabolic medicine, and current chair of The Familial Hypercholesterolaemia-Australasia Network. He is the clinical lead of Cardiometabolic Services in the Department of Cardiology at Royal Perth Hospital and is Professor of Cardiometabolic Medicine in the University of Western Australia. Research interests include lipid disorders, obesity and cardiovascular prevention, and clinical interest focuses on delivering improved health care for high risk dyslipidemias. He has authored over 500 published works and is on the editorial board of Atherosclerosis, Clinical Science, Metabolism, Journal of Clinical Lipidology, and Current Opinion in Lipidology.

Kevin Jon Williams
Kevin Jon Williams

M.D.

Dr. Williams is a Medical and Scientific Advisory Board member for Gemphire. An avid researcher with many published works to his credit, Dr. Williams has performed groundbreaking studies in the areas of lipoproteins, atherosclerosis, and more recently, type 2 diabetes. Examples include the ‘Response-to-Retention’ hypothesis of early atherogenesis, identification of sulfatase-2 as an inhibitor of atherogenic remnant lipoprotein removal by the liver in type 2 diabetes, and discovery of the NSAPP oxide transport chain, which is a key regulator of balanced insulin signaling. Dr. Williams serves on the editorial board of Arteriosclerosis, Thrombosis and Vascular Biology (an American Heart Association journal) and Rambam (Maimonides) Medical Journal.